Candid Therapeutics IPO: Biotech Goes Public via Rallybio Reverse Merger

Candid Therapeutics is set to go public via a reverse merger with Rallybio. This autoimmune and inflammatory biotech secured $505 million in funding. This significant Candid Therapeutics IPO marks a major step for the company.

The company focuses on developing therapies for various autoimmune and inflammatory conditions. This strategic move facilitates its entry into the public market.

What Happened

Candid Therapeutics is becoming a public company through a reverse merger. The transaction involves Rallybio, an established entity.

Concurrently, Candid Therapeutics raised $505 million in new funding. This information comes from Endpoints News.

Details From Sources

Candid Therapeutics operates from San Diego and Shanghai. Its primary therapeutic area is autoimmune and inflammatory conditions. Rallybio, its merger partner, is listed on Nasdaq under the ticker RLYB. (Endpoints News)

Conclusion

Candid Therapeutics is going public through a reverse merger with Rallybio. This move was accompanied by a successful $505 million funding round.

The company maintains its focus as an autoimmune and inflammatory biotech. This public listing represents a key milestone.

FAQ

• Q1: What is Candid Therapeutics’ primary focus?
  Answer: Candid Therapeutics is an autoimmune and inflammatory-focused biotech.
• Q2: How is Candid Therapeutics going public?
  Answer: Candid Therapeutics is going public through a reverse merger with Rallybio.
• Q3: What is the amount of funding Candid Therapeutics secured?
  Answer: Candid Therapeutics concurrently raised $505 million.
• Q4: Where are Candid Therapeutics’ main locations?
  Answer: Candid Therapeutics is based in San Diego and Shanghai.
• Q5: What is Rallybio’s stock exchange listing?
  Answer: Rallybio is listed on Nasdaq under the ticker RLYB.